Home -> Law Blog Directory -> Class Action Blogs -> The UCL Practitioner
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Class Action
: The UCL PractitionerStatement of issues on review in Clayworth v. Pfizer, Inc.
By Kimberly A. Kralowec
The Supreme Court has posted its statement of issues on review in Clayworth v. Pfizer, Inc., no. S166435. The UCL-related issues are particularly interesting:
(1) When plaintiffs pay overcharges on goods or services as a result of the anticompetitive conduct of defendant sellers but recover the overcharges through increased prices at which the goods or services are sold to end users, may defendants assert a "pass-on" defense and argue that plaintiffs were not injured because they did not suffer financial loss as a result of the anticompetitive conduct? (2) Is restitution available under the Unfair Competition Law (Bus. & Prof. Code, 17200 et seq.) to plaintiffs who recovered from third persons the overcharges paid to defendants? (3) When plaintiffs recover from third persons the overcharges paid to defendants, have they suffered actual injury and lost money or property for purposes of establishing standing under the Unfair Competition Law, as amended by Proposition 64?
I've added Clayworth to my list of pending California Supreme Court cases of interest to UCL and class action practitioners. I also added Brinker to that list.
Full post as published by The UCL Practitioner on November 24, 2008 (boomark / email).
Bextra Product Recall
Find a Bextra Lawyer
Bextra Injury Risks
Bextra Increases Risk of Fatal Heart Attack
FDA Issues Update on Safety Review Orlistat
Orlistat FDA Issues Update on Safety Review
Pfizer, Pharmacia
Found Guilty of Medicaid Fraud
Pfizer
Will Pay $975,000 In Clean Air Settlement
Aurora Loan Faces Class Action over Mortgage Review Services
Aurora Loan Faces Class Action over Mortgage Review Services
FDA Review of Prostate Cancer Treatment Prompts Warning of Risk for Diabetes
Prostate Cancer Treatment FDA Review Prompts Warning of Risk for Diabetes
Xigris
Study Prompts FDA Safety Review

Clayworth v. Pfizer: Supreme Court Extends Time For Granting Review
Bextra and Celebrex Cases Settled
FDA decides to perform second safety review of Pfizers Chantix
Pfizer Pulls Lipitor Ads featuring DR. Jarvik
Pfizer Agrees to $894 Million Celebrex and Bextra Settlement








